

AD \_\_\_\_\_

GRANT NUMBER DAMD17-96-1-6109

TITLE: The Possible Role of E2F in Rat Mammary Carcinogenesis

PRINCIPAL INVESTIGATOR: Traci A. Lee

CONTRACTING ORGANIZATION: University of Wisconsin  
Madison, Wisconsin 53706

REPORT DATE: August 1998

TYPE OF REPORT: Annual

PREPARED FOR: Commanding General  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19981030 061

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.</small>				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1998		3. REPORT TYPE AND DATES COVERED Annual (15 Jul 97 - 14 Jul 98)
4. TITLE AND SUBTITLE The Possible Role of E2F in Rat Mammary Carcinogenesis			5. FUNDING NUMBERS DAMD17-96-1-6109	
6. AUTHOR(S) Ms. Traci A. Lee				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin Madison, Wisconsin 53706			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)  My project, as described in the last annual report, was to coexpress E2F wild type and mutant proteins, ras, and GFP from the same viral vector and infuse the viruses into rat mammary glands to see if E2F wild type and mutant proteins could cooperate or interfere with ras mediated mammary carcinogenesis. While cloning of the viral vectors was successful and protein expression of the E2F proteins was evident, there was no ras expression from the IRES (internal ribosome entry site) as monitored by Westerns or NIH 3T3 transformation assays. Therefore, using viral infusion to investigate the interaction between ras and E2F proteins was not possible. As a result, I used tissue culture assays to investigate these two proteins in transformation. While E2F1 was unable to cause transformation by itself, a E2F1 del417-437 mutant interfered with ras transformation. Interestingly, this mutant does not affect cell cycle progression and does not appear to be toxic. Therefore, E2F1 del417-437 may be affecting transformation-specific E2F targets. Endogenous E2F targets are being investigated by a chromatin immunoprecipitation assay.				
14. SUBJECT TERMS Breast Cancer  E2F transcription factors, Activated c-Ha-ras, transformation			15. NUMBER OF PAGES 19	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

10081030061

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

\_\_\_\_ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Peppy Carlson 8/13/98  
PI - Signature Date

3 Grace Lee 8/12/98

## **TABLE OF CONTENTS**

	<b>PAGE NUMBER</b>
<b>I. FRONT COVER</b>	<b>1</b>
<b>II. STANDARD FROM</b>	<b>2</b>
<b>III. FOREWORD</b>	<b>3</b>
<b>IV. TABLE OF CONTENTS</b>	<b>4</b>
<b>V. INTRODUCTION</b>	<b>5</b>
<b>VI. BODY</b>	<b>6</b>
<b>VII. CONCLUSIONS</b>	<b>16</b>
<b>VIII. REFERENCES</b>	<b>17</b>

## INTRODUCTION

Tumors arise when cells escape the controls of cell growth and undergo an inappropriate expansion in cell number. The decision for a cell to divide, and thus expand in number, is made in the G1 phase of the cell cycle before cells replicate their DNA in S phase. It is during the G1 to S phase transition that a cell commits to activating genes whose products are required for DNA replication and cell cycle progression. Many factors which control the G1 to S phase transition of the cell cycle are implicated in the formation of cancer. The activation of several G1/S-phase regulated genes is mediated via a family of transcription factors called E2F (26). The abundance and activity of the E2F transcription factors are tightly regulated by positive and negative regulators of the G1 to S phase transition. These regulators are often mutated in breast cancer in such a way that they could upregulate E2F activity (11). The retinoblastoma (Rb) tumor suppressor protein, a direct negative regulator of E2F activity, is lost or inactivated in approximately 30% of breast carcinomas (27, 29). In addition, the activity of positive regulators of E2F activity, such as cyclin D1 and cyclin E, is increased in many breast cancers. Cyclin D1 has been found to be increased in 45% of breast tumor biopsies (2) and studies show altered patterns of expression for cyclin E in numerous breast cancer cell lines and primary breast tumors (13, 14, 15, 21).

The mechanism by which Rb and the G1 cyclins (cyclin D1 and cyclin E) are involved in the formation of breast cancer is unknown, but they are all regulators of E2F activity. While E2F family members have been shown to function as oncogenes in standard transformation assays (1, 8, 12, 25, 30), an *in vivo* investigation of the involvement of E2F in breast cancer development has yet to be done. Because rat mammary carcinoma mirrors human breast cancer in many ways, I proposed to overexpress wildtype E2F family members in rat mammary glands using a replication defective retrovirus (9). Last year, I determined that the E2F4 virus did not cause a visible phenotype in the rat mammary gland. This result suggested that E2F4 was not able to cause breast cancer when overexpressed alone. Since activated ras is able to cause tumors in the rat mammary gland when expressed alone in the rat mammary gland, I proposed to overexpress either wildtype or mutant E2F family members in combination with the oncogenic protein ras in rat mammary glands using a replication defective retrovirus. By looking at the effect of E2F proteins on ras mediated mammary carcinogenesis, I could determine if E2F wild type or mutant proteins can cooperate or interfere with activated ras to cause mammary carcinoma.

19981030 061

## BODY

### Materials and Methods

#### Cloning and plasmids used

The pJLR, pLCG, and pJLR-HrasA plasmids were obtained from the Gould laboratory (28). The priboEJras plasmid, containing the second and third exons of an activated c-Ha-ras under the expression of the ribosomal L323A promoter, was obtained from Mary Ellen Perry's laboratory (7). The pEMC-F vector which contains an IRES (Internal Ribosomal Entry Site) was obtained from W. French Anderson's laboratory (19). The mE2F1 cDNA was available in our laboratory and the hE2F4 cDNA was obtained from Rene Benards (1, 16). The pCMV E2F1 and pCMV E2F1 E138 vectors were from Joseph Nevins laboratory (5). The pE2F1 del417-437 vector was obtained from Ed Harlow's laboratory (10).

The pIR vector was made by PCR amplifying the activated form of the c-Ha-ras gene from the pJLR-HrasA vector with primers containing the appropriate restriction sites. PCR products were digested with the proper restriction enzymes, isolated, and inserted into the pEMC-F vector, placing it in frame downstream of the IRES. Then the IRES-activated c-Ha-ras cassette was removed from the pEMC-F-ras vector with the appropriate restriction enzymes, isolated, and inserted into the pLCG SalI site. The pLCG-E2F and pIR-E2F vectors were cloned by PCR amplification of different E2F cDNA vectors with primers which have BamHI sites. PCR products were digested with BamHI, isolated, and inserted into the BamHI site of the vector. Cloning was done using standard procedures (23). All inserts were sequenced for proper orientation and high fidelity PCR.

#### Cell Culture

NIH 3T3 cells used in focus forming transformation assays are from ATCC (American Type Culture Collection) and were grown in DMEM with 10% BCS (Bovine Calf Serum) and 1% P/S (Penicillin / Streptomycin) in a 5% CO<sub>2</sub> incubator at 37°C.

NIH 3T3 cells used for serum starvation stimulation assays were grown in DMEM with 5% BCS and 1% P/S in a 5% CO<sub>2</sub> incubator at 37°C. In a starvation-stimulation procedure, Cells at about 50% confluency were placed in starvation media for 48-60 hours. Cells were then stimulated by adding stimulation media for the indicated times. Starvation media used was DMEM with 0.5% BCS and 1% P/S. Stimulation media used was DMEM with 10% BCS and 1% P/S.

Hela cells were grown in suspension in Joklik's media with 10% BCS and 1% P/S, and 1% glutamine using a stirring flask at 37°C without CO<sub>2</sub> regulation.

### Whole cell protein extraction

Cells were grown in T225 flasks and harvested by trypsinization. Cells were pelleted by centrifugation at 1000 rpm for 5 min. in a tabletop centrifuge and the supernatant was removed. Cell pellets were stored at -20° C. Whole cell protein extractions were done by thawing the cell pellet that was harvested from one T225 flask briefly at 37° C. The cells were then kept on ice and 0.5 ml of lysis buffer [ 50mM Tris, pH 8.0; 5mM EDTA; 150mM NaCl; 0.5% NP-40; 1mM PMSF] was mixed with the pellet. After leaving the cells on ice for 20 min., the cells were further mixed for 1 min. and then the lysate was placed in a 1.5 ml microcentrifuge tube and spun at 14,000 rpm for 5 min. at 4° C in a microcentrifuge. The supernatant is then assayed for protein content and kept for Western studies.

### Western analysis

Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions on a 10% gel by standard techniques (23). Proteins were transferred to nitrocellulose electrophoretically and probed with antibodies against E2F proteins (antibodies from Santa Cruz) or with antibodies against TBP as a standardization control (from Richard Burgess's laboratory) (3). Proteins were detected by enhanced chemiluminescence (reagents and protocol from Amersham).

### NIH 3T3 focus forming transformation assay

Transfection buffers and procedures used are as described in Chen and Okayama (4) except for the following: 10 ugs of E2F or empty expressor plasmid and indicated amounts of the priboEJras vector were used for each transfection. Sonicated salmon sperm DNA was added to the transfection DNA to make a total DNA content equal 20ugs per transfection. After cells were allowed to grow for 2 weeks, cells were fixed and stained using the following procedure. Media was removed and cells were rinsed with PBS. Cells were fixed in 10% buffered formalin (formaldehyde) for at least 5 min. Formalin was removed and cells were stained with 0.14% methylene blue in H2O for 10 min or longer. Stain was removed and cells were washed extensively with H2O and allowed to dry.

### Flow analysis

Cells were harvested by trypsinization and counted with a hemacytometer. Cells were then resuspended  $5 \times 10^5$  cells per 300ul media. An equal volume of 20ug/ml Hoechst 33342 was added and cells were then incubated for 30 min. at 37° C, filtered through a 30um nylon mesh, and treated with propidium iodide (PI) to a final concentration of 5ug/ml. Cells were then analyzed using a FACSstar machine to detect transfected (using GFP as a marker) and live (by gating out PI stained cells) cells and to determine the


cell cycle stage (using Hoechst 33342 to stain DNA) of the cells. Analysis was conducted by the staff at the flow cytometry facility at UW hospital.

## Results and Discussion:

Instead of using the pJLR vector as in the studies done last year, I used a different retroviral vector which expresses an enhanced form of the green fluorescent protein (eGFP) instead of the neomycin resistance gene as a selectable marker. eGFP is a protein marker that will emit a green light in the presence of blue light. As a result, visualization and selection of infected cell clones and quicker titering of single cell clones *in vitro* and *in vivo* would be possible (20). I received a retroviral vector which contained eGFP, called pLCG, from Phil Watson in the Gould laboratory.

From the last annual report, I had decided to coexpress E2F with ras by adding an IRES to the pLCG vector in order to express the two proteins from the same MMLV LTR promoter. E2F1 would be the first gene driven by the promoter and the activated form of c-Ha-ras is the second gene (see "pIR" vector). For controls, the parental vector, pLCG, which does not have the IRES-ras cassette, and vectors which expressed luciferase (luc) instead of E2F were used. A schematic of all vectors are shown in Figure 1.

Figure 1. Schematics of all viral vectors






Studies in tissue culture indicate that ras and E2F cooperate to transform rat embryo fibroblasts even though ras or E2F is unable to transform the cells when expressed alone (1, 12). A recent study has shown that transgenic coexpression of E2F1 and ras in mouse skin leads to a severe cancer phenotype which is not seen when ras or E2F1 is expressed alone (22). While cooperation between ras and E2F1 has been demonstrated in vivo, results seen in mouse skin can be very different than what is seen in the rat mammary gland. Since the rat mammary gland is very similar to human mammary tissue, these studies should give insight on the role of E2F1 in the tissue specific environment of the mammary gland for rats and possibly, humans. pIR-wild type E2F1, pIR-luc, pLCG-wild type E2F1, and pLCG-luc would be used to test this issue.

I also coexpressed ras with the E2F1 mutant E138 which contains two amino acid mutations within its DNA binding domain. This mutation interferes with the ability of E2F1 and other E2F proteins to bind to DNA. Ras has been shown to activate many different pathways (18). One of the proteins that ras activates is cyclin D1 which can increase E2F activity (6, 17). If ras causes tumors using a E2F dependent pathway in the mammary gland, expression of a dominant negative E2F should cause a decrease in the number and/or size of ras initiated tumors. pIR-E2F1 E138, pIR-luc, pLCG-E2F1 E138, and pLCG-luc would be used to test this issue.

I first determined if cells which contained the viral vectors were producing the vector proteins properly. I was able to detect human E2F1 by Western analysis (Figure 2) and luciferase by a luciferase assay (data not shown), but I could not detect the ras protein in Westerns (data not shown). I was also unable to detect GFP (by fluorescence) in the pIR vectors but the could be detected in the pLCG vectors (data not shown).


Figure 2. E2F1 Western of PA317 cells lipofected with E2F1 and E2F1 E138 viral vectors. TBP Western was used as a standardization control. Hela nuclear extract used as a positive control for E2F1 detection.



To determine if functional ras was being made from the pIR vectors as well as test my vectors in a tissue culture assay before using them in the rat mammary gland, I used a NIH 3T3 transformation assay. pIR based vectors did not cause transformation of the NIH 3T3 cells while the positive control for transformation, the priboEJras formed several foci (data not shown). In conclusion, the pIR vectors were not making functional activated ras. The IRES may have not been working and could also have interfered with the expression of GFP driven by the downstream CMV promoter.


Since the pIR vectors did not produce functional ras or GFP proteins, I could not pursue making viruses for infusion into rat mammary glands. In order to ask the same question, "Can wild type or mutant forms of E2F transcription factors cooperate or interfere with ras mediated transformation?", I used separate expression constructs for E2F1 and activated ras (see Figure 3) in the NIH 3T3 transformation assay. Transformation assays with the E2F expression vectors alone, produced no foci above background vector alone levels (data not shown). At the recommended level of ras vector, 20ug per transfection, E2F expression constructs seemed to have no effect in tissue culture dishes almost confluent with transformed foci. I proceeded to titrate down the amount of ras vector. While 10ug and 2ug of ras still contained too many foci to count, countable foci were detected at 0.5, 0.2, and 0.1 ug of ras vector (data not shown).

Figure 3: Schematics of nonviral E2F1 and ras vectors used in NIH 3T3 transformation assays



At the levels of 0.1, 0.2, and 0.5 ugs of priboEJras, I discovered that the mutant E2F1 protein, del417-437, could consistently inhibit ras mediated transformation. Figure 4 shows a representative graph of transformation results with the del417-437 mutant. Studies of the wild type and the E138 mutant E2F1 are still inprogress.

Figure 4: E2F1 del417-437 inhibited ras mediated transformation in a NIH 3T3 focus forming assay at the ras vector concentrations of 0.1 ug and 0.2 ug per transfection.



To investigate how the E2F1 del417-437 mutant could inhibit ras mediated transformation, I looked at the effect of the mutant on cell cycle kinetics. DNA profiles for NIH 3T3 cells transfected with the del417-437 mutant looked normal when compared to vector alone in 60 hr. serum starved and stimulated cells (see Figure 5). To rule out the idea that E2F1 del417-437 is affecting a cell cycle gene that is very stable, resulting in no effect in a 60hr starvation stimulation assay because the critical target protein is still in sufficient amounts, I also analyzed cell cycle kinetics of 7 day starved and stimulated cells and 3 day log growing cells. Again, I saw no change in cell cycle kinetics between E2F1 del417-437 and vector alone transfected cells (see Figure 6 and 7). In addition, I see the same percentage of cells transfected with del417-437 and vector alone suggesting that apoptosis is not playing a role in inhibiting ras transformation. In support of this, other studies show that E2F1 del417-437 does not cause apoptosis (24). We suggest that E2F1 del417-437 is affecting transformation specific E2F targets. We are currently investigating E2F target genes using a chromatin immunoprecipitation assay.

Figure 5: Comparison of pCMV and E2F1 del417-437 transfected NIH 3T3 60 hr. serum starved and stimulated cells using flow cytometry.




Figure 6: Comparison of pCMV and E2F1 del417-437 transfected NIH 3T3 seven day serum starved and stimulated cells using flow cytometry.





Figure 7: Comparison of pCMV and E2F1 del417-437 transfected NIH 3T3 log growing cells using flow cytometry.

pCMV GFP+ cells

G0/G1 = 76.87%

S = 10.67%

G2/M = 11.21%




E2F1 del417 GFP+ cells

G0/G1 = 72.37%

S = 13.46%

G2/M = 13.22%



## CONCLUSIONS

E2F1 mutant del417-437 inhibits ras-mediated transformation apparently without causing a cell cycle arrest or cell death. We suggest that E2F1 del417-437 is affecting transformation specific E2F targets. Comparison of the del417-437 mutant with the wild type and other E2F1 mutant proteins should give more insight into the mechanism of inhibition of ras mediated transformation. These studies are currently being done. Also, we are currently investigating E2F target genes using a chromatin immunoprecipitation assay.



## REFERENCES

1. **Beijersbergen, R. L., R. M. Kerkhoven, L. Zhu, L. Carlée, P. M. Voorhoeve, and R. Bernards.** 1994. E2F4, a new member of the E2F gene family, has oncogenic activity and associates with p107 *in vivo*. *Genes Dev.* 8:2680-2690.
2. **Buckley, M. F., K. J. E. Sweeney, J. A. Hamilton, R. L. Sini, D. L. Manning, R. I. Nicholson, A. deFazio, C. K. W. Watts, E. A. Musgrove, and R. L. Sutherland.** 1993. Expression and amplification of cyclin genes in human breast cancer. *Oncogene* 8:2127-2133.
3. **Buermeier, A. B., S. M. McMahon, L. A. Strasheim, and P. J. Farnham.** 1995. Identification of cis-acting elements that can obviate a requirement for the C-terminal domain of RNA polymerase II. *J. Biol. Chem.* 270:6798-6807.
4. **Chen, C., and H. Okayama.** 1987. High-efficiency transformation of mammalian cells by plasmid DNA. *Mol. Cell Bio.* 7:2745-2752.
5. **Cress, W. D., D. G. Johnson, and J. R. Nevins.** 1993. A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. *Mol. Cell. Biol.* 13:6314-6325.
6. **Filmus, J., A. I. Robles, M. J. Wong, L. L. Colombo, and C. J. Conti.** 1994. Induction of cyclin D1 overexpression by activated ras. *Oncogene* 9:3627-3633.
7. **Finlay, C., P. Hinds, and A. Levine.** 1989. The p53 proto-oncogene can act as a suppressor of transformation. *Cell* 57:1083-1093.
8. **Ginsberg, D., G. Vairo, T. Chittenden, Z.-X. Xiao, G. Xu, K. L. Wydner, J. A. DeCaprio, J. B. Lawrence, and D. M. Livingston.** 1994. E2F-4, a new member of the E2F transcription factor family, interacts with p107. *Genes Dev.* 8:2665-2679.
9. **Gould, M. N., and R. Zhang.** 1991. Genetic regulation of mammary carcinogenesis in the rat by susceptibility and suppressor genes. *Environ. Health Perspectives* 93:161-167.
10. **Helin, K., E. Harlow, and A. Fattaey.** 1993. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. *Mol. Cell. Biol.* 13:6501-6508.
11. **Hunter, T., and J. Pines.** 1994. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. *Cell* 79:573-582.
12. **Johnson, D. G., W. D. Cress, L. Jakoi, and J. R. Nevins.** 1994. Oncogenic capacity of the E2F1 gene. *Proc. Natl. Acad. Sci. USA* 91:12823-12827.
13. **Keyomarsi, K., D. Conte Jr., W. Toyofuku, and M. Fox.** 1995. Deregulation of cyclin E in breast cancer. *Oncogene* 11:941-950.
14. **Keyomarsi, K., N. O'Leary, G. Molnar, E. Lees, H. J. Fingert, and A. B. Pardee.** 1994. Cyclin E, a potential prognostic marker for breast cancer. *Cancer Res.* 54:380-385.
15. **Keyomarsi, K., and A. B. Pardee.** 1993. Redundant cyclin overexpression and gene amplification in breast cancer cells. *Proc. Natl. Acad. Sci. USA* 90:1112-1116.

16. Li, Y., J. E. Slansky, D. J. Myers, N. R. Drinkwater, W. G. Kaelin, and P. J. Farnham. 1994. Cloning, chromosomal location, and characterization of mouse E2F1. *Mol. Cell. Biol.* 14:1861-1869.
17. Liu, J.-J., J.-R. Chao, M.-C. Jiang, S.-Y. Ng, J. J.-Y. Yen, and H.-F. Yang-Yen. 1995. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. *Mol. Cell. Biol.* 15:3654-3663.
18. Marshall, M. S. 1995. Ras target proteins in eukaryotic cells. *FASEB Journal* 9:1311-1318.
19. Morgan, R. A., L. Couture, O. Elroy-Stein, J. Ragheb, B. Moss, and W. F. Anderson. 1992. Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. *Nuc. Acids Res.* 20:1293-1299.
20. Muldoon, R. R., J. P. Levy, S. R. Kain, P. A. Kitts, and C. J. Link Jr. 1997. Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene. *BioTechniques* 22:162-167.
21. Nielsen, N. H., C. Arnerlov, S. O. Emdin, and G. Landberg. 1996. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. *British Journal of Cancer* 74:874-880.
22. Pierce, A. M., S. M. Fischer, C. J. Conti, and D. G. Johnson. E2F-1 induces epidermal hyperplasia and contributes to skin tumor formation in transgenic mice. submitted
23. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
24. Shan, B., and W.-H. Lee. 1994. Deregulated expression of E2F1 induces S-phase entry and leads to apoptosis. *Mol. Cell. Biol.* 14:8166-8173.
25. Singh, P., S. H. Wong, and W. Hong. 1994. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. *EMBO J.* 13:3329-3338.
26. Slansky, J. E., and P. J. Farnham. 1996. Introduction to the E2F family: protein structure and gene regulation, p. 1-30. *In* P. J. Farnham (ed.), Transcriptional control of cell growth: the E2F gene family. Springer-Verlag, New York.
27. Varley, J. M., J. Armour, J. E. Swallow, A. J. Jeffreys, B. A. J. Ponder, A. T'Ang, Y.-K. T. Fung, W. J. Brammer, and R. A. Walker. 1989. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. *Oncogene* 4:725-729.
28. Wang, B., W. S. Kennan, J. Yasukawa-Barnes, M. J. Lindstrom, and M. N. Gould. 1991. Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retrovirus vectors. *Cancer Res.* 51:2642-2648.
29. Wang, N. P., H. To, W.-H. Lee, and E. Y.-H. P. Lee. 1993. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. *Oncogene* 8:279-288.

30. Xu, G., D. M. Livingston, and W. Krek. 1995. Multiple members of the E2F transcription factor family are the products of oncogenes. *Proc. Natl. Acad. Sci. USA* **92**:1357-1361.